Untreated type 2 diabetic patients with ischemic heart disease
Conditions
Interventions
Linagliptin 5mg once a day for 3 months
Voglibose 0.3mg three times a day for 3 months
Sponsors
Chiyukai Fukuoka Wajiro hospital
Division of cardiovascular medicine, Saga university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients 1) with ischemic heart disease (old myocardial infarction, stable angina pectoris, silent myocardial ischemia, history of percutaneous transluminal coronary angioplasty, history of coronary artery bypass grafting) 2) with untreated diabetic melitus and HbA1c (NGSP) less than or equal to 6.4% 3) with unchanged medication during latest 1 month 4) aged 20 years old or older
Exclusion criteria
Exclusion criteria: 1. Patients with liver disease (ALT or AST level is over 100IU/L, total Bil level is over 2.5mg/dl). 2. Patients with congenital heart disease. 3. Patients with highly advanced cardiac dysfunction. 4. Patients with endocrine disease. 5. Patients with malignancy or inflammatory disease. 6. Patinets with highly advanced respiratory disease (containing pulmonary arterial pulmonary hypertension. 7. Patients with cranial nerve disease or locomotor apparatus disease, and severely compromised daily life. 8. Patients with severe hypertension. 9. Patients administrated steroid or immune suppressor. 10. Patients with type1 DM or type2 DM and HbA1c (NGSP) 6.5% or more. 11. Patients during pregnancy or with possibility of pregnancy. 12. Patients administrated catecholamine. 13. Patients with symptomatic hypotension. 14. Patients with significant LVOT obstruction (Hypertrophic obstructive cardiomyopathy or aortic stenosis). 15. Patients without written consent. 16. Patients recognized inadequate by primary doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of RHI(Reactive hyperemia index) | — |
Secondary
| Measure | Time frame |
|---|---|
| blood glucose, serum insulin level, HbA1c(NGSP), LDL, HDL, Triglyceride, total cholesterol, urine albumin/creatinine ratio, MDA-LDL, hs-CRP, IL-8, MCP-1, periostin, RAGE, HMW adiponectin, NT-pro BNP, active GLP1 | — |
Countries
Japan
Contacts
Public ContactTaku Koyama
Chiyukai Fukuoka Wajiro hospital Cardiovascular medicine
Outcome results
None listed